us tavr exce high end expect
rais estim target price reiter
outperform top pick ew
much anticip debat ew deliv impress upsid us tavr
us tavr grew vs factset consensu estim acceler
growth buck season slowdown typic ew management attribut
strength us tavr growth unexpect bolu patient refer treat
driven part strong superior result low-risk tavr present march
comment consist convers clinician remain
open question whether step-up us tavr volum repres
bolu potenti ramp reiter outperform rate ew rais
target price
mgmt market outlook commentari like temper investor expect
management commentari suggest bolu patient could pull
volum forward futur quarter result tavr volum growth
could slow low doubl digit due challeng comp weve temper
growth expect slightli although weve rais estim dollar basi
progress next sever quarter would surpris see overal
tavr volum stabil higher level growth driven factor
caus impress step growth past two quarter tune
guidanc rais high end rang management rais sale guidanc high
end bil rang tavr guidanc high end bil rang
management rais ep guidanc weve rais project
line guidanc outer year tavr project remain
consensu mgmt intermedi long-term expect
valuat target price base ev/ebitda multipl
unch bil ebitda estim bil risk product delay
unexpect share loss potenti litig regulatory/qu issu
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
global manufactur provid
medic devic equip structur valvular heart diseas
critic care
one-year valuat scenario base
ev/ebitda ebitda
scenario base emerg segment deliv growth
high-growth segment grow growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda grey
scenario base emerg segment deliv growth
high-growth segment grow growth grow
 close
addit detail takeaway
ww tavr mil mil y/i
compani estim grew in-lin ww tavr growth remain stabl
compani continu exercis price disciplin ew tavr sale
in-lin tavr procedur growth driven unexpect bolu tavr
treatment follow strong clinic trial data ou tavr procedur grew
compani growth compar europ tavr procedur grew
teen ew growth compar sale japan also strong
manag focus increas avail tavr launch sapien ultra
on-going eu compani expect sapien ultra account tavr sale
 europ manag indic earli tavr clinic trial
approxim half enrol focus indic expans patient suffer
sever yet report symptom compani expect fulli enrol trial
vs previou expect compani expect underli tavr sale
high-end bil rang expect tavr procedur grow ldd
slower given tougher comp
tmtt mitral tricuspid program continu progress
tmtt sale mil driven continu roll-out pascal eu compani
remain focus physician train compani continu enrol patient
clasp pivot trial studi pascal patient primari degen mitral valv
diseas addit compani receiv approv enrol patient clasp pivot
trial patient function mitral diseas initi enrol trial
mitral replac compani remain track initi pivot trial sapien
end year tricuspid repair compani made decis acceler
 tricuspid pivot trial use pascal plan start activ site end year
compani expect tmtt sale mil estim ww
tmtt opportun reach bil compani expect doubl tmtt
surgic structur heart mil mil y/i
solid underli growth driven continu adopt newer premium aortic valv
ou strength partial off-set lower surgic aortic heart valv procedur
tavr adopt expand compani also continu launch inspiri resilia aortic valv
indic increas util driven increas demand among younger activ
patient manag expect european regulatori approv harpoon system around
end year compani expect sale mil
critic mil mil y/i cc
sale y/i exclud casm acquisit underli ex-casm
integr casm mil sale underway compani expect sale
top end mil rang
compani guid high-end bil sale rang high-
end tavr rang bil ep guidanc also rais
fx expect neg impact sale mil
compani expect sale bill ep
 op margin bp estim
bottom line sale net cog lower tax rate partial off-set
higher sg higher deliv ep estim
gross margin bp y/i driven favor fx product mix partial
off-set spend support new european devic regul manufactur
estimate bpop bpnon-op bpnet chg y/i charl martineau pm univers toronto octob
chang model
increas sale estim ep estim
also made minor adjust top-lin project beyond increas
sale estim per year averag outer year ep estim rise
figur chang model
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
